

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Innovent

信達生物製藥

INNOVENT BIOLOGICS, INC.

(Incorporated in the Cayman Islands with Limited Liability)

(Stock Code: 1801)

GRANT OF SHARE OPTIONS AND RESTRICTED SHARES

GRANT OF SHARE OPTIONS

This announcement is made pursuant to the existing Rule 17.06A of the Listing Rules (effective until December 31, 2022). The Board announces that on December 9, 2022, the Company granted 1,020,698 Options to 5 Grantees in accordance with the terms of the Post-IPO ESOP (the “**Option Grants**”), subject to acceptance by the Grantees.

Details of the Option Grants

The details of the Options granted to the Grantees are as follows:

Grant Date:	December 9, 2022
Number of Grantees:	5
Total number of new Shares to be subscribed upon full exercise of the Options granted:	1,020,698
Consideration for the Option Grants:	HK\$1.00 to be paid by each Grantee upon acceptance of the Options granted
Exercise price of the Options granted:	HK\$32.25 per Share
Validity period of the Options:	The validity period of the Options shall be ten years from the Grant Date and the Options shall lapse at the expiry of the validity period.
Vesting period:	The Options granted to the Grantees shall vest in the Grantees as follows: <ul style="list-style-type: none">• 75% shall vest on December 9, 2025; and• 25% shall vest on December 9, 2026.

The Option Grants are subject to individual performance result requirement as set out in the grant letter entered into between the Company and each Grantee.

Exercise Price

The exercise price of the Options of HK\$32.25 per Share represents the highest of (i) the closing price of the Shares of HK\$32.25 per Share as stated in the daily quotation sheet issued by the Stock Exchange on the Grant Date, (ii) the average closing price of the Shares of HK\$28.39 per Share as stated in the daily quotation sheets issued by the Stock Exchange for the five business days immediately preceding the Grant Date, and (iii) the nominal value of each Share, which is US\$0.00001.

None of the Option Grants will be subject to approval by the Shareholders, and none of the Grantees is a Director, chief executive or substantial shareholder of the Company or an associate (as defined in the Listing Rules) of any of them.

Reasons for and benefit of the Option Grants

The Board is of the view that the Option Grants can (i) retain, incentivize and reward the Grantees and (ii) encourage Grantees to work towards enhancing the value of the Company and its Shares.

GRANT OF RESTRICTED SHARES

On December 9, 2022, the Company granted 1,259,407 Restricted Shares to 5 Grantees in accordance with the terms of the 2020 RS Plan (the “**RS Grants**”), subject to acceptance by the Grantees and the satisfaction of performance targets.

None of the RS Grants will be subject to approval by the Shareholders, and none of the Grantees is a Director, chief executive or substantial shareholder of the Company or an associate (as defined in the Listing Rules) of any of them.

In accordance with the terms of the 2020 RS Plan, the Restricted Shares are granted to the Grantees under the following terms:

- each of the Restricted Shares is granted for nil consideration;
- each of the Restricted Shares to be granted to the Grantees represents the right to receive one Share on the date it vests;

- the number of Restricted Shares to vest on such date is subject to individual performance result requirement as set out in the grant letter entered into between the Company and each Grantee; and
- the Restricted Shares shall vest as follows:
 - 75% shall vest on December 9, 2025; and
 - 25% shall vest on December 9, 2026.

Market Value

Based on the closing price of HK\$32.25 per Share as stated in the daily quotation sheet issued by the Stock Exchange on the Grant Date, the market value of the Restricted Shares granted to the Grantees amounts to approximately HK\$40,615,876.

Reasons for and benefits of the RS Grants

The Company believes that the Option Grants can (i) encourage and enable the Grantees to share the success of the Company and (ii) assure a closer identification of their interests with those of the Group, thereby stimulating their efforts on the Group's behalf and strengthening their desire to remain with the Group.

The 2020 RS Plan does not constitute a share option scheme pursuant to the existing Chapter 17 (effective until December 31, 2022) of the Listing Rules and is a discretionary scheme of the Company. From January 1, 2023, the Company will comply with the new Chapter 17 (which will come into effect on January 1, 2023) in accordance with the transitional arrangements for the existing share award scheme.

DEFINITIONS

“Board”	the board of Directors
“Company”	Innovent Biologics, Inc. 信達生物製藥, an exempted company with limited liability incorporated under the laws of the Cayman Islands on April 28, 2011
“Directors”	the directors of the Company
“Grant Date”	December 9, 2022
“Grantees”	the employees and consultant of the Group who were granted Options and/or Restricted Shares in accordance with the Post-IPO ESOP and/or the 2020 RS Plan respectively on the Grant Date
“Group”	the Company and its subsidiaries
“HK\$”	Hong Kong dollar, the lawful currency of Hong Kong

“Hong Kong”	the Hong Kong Special Administrative Region of the People’s Republic of China
“Listing Rules”	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited
“Option(s)”	option(s) to subscribe for or acquire Shares which is/are granted under the Post-IPO ESOP
“Option Grants”	the grant of an aggregate of 1,020,698 Options to 5 Grantees in accordance with the terms of the Post-IPO ESOP
“Post-IPO ESOP”	the post-IPO share option scheme adopted by the Company on June 12, 2018
“Restricted Share(s)”	restricted share(s), being a contingent right to receive Shares awarded under the 2020 RS Plan
“RS Grants”	the grant of an aggregate of 1,259,407 Restricted Shares to 5 Grantees in accordance with the terms of the 2020 RS Plan
“Shareholder(s)”	holder(s) of Shares in the Company
“Shares”	ordinary shares in the issued capital of the Company with a nominal value of US\$0.00001
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“subsidiary(ies)”	has the meaning ascribed to it by the Listing Rules
“substantial shareholder”	has the meaning ascribed to it by the Listing Rules
“US\$”	U.S dollars, the lawful currency of the United States of America
“2020 RS Plan”	the restricted share plan adopted by the Company on June 12, 2020

By Order of the Board
Innovent Biologics, Inc.
Dr. De-Chao Michael Yu
Chairman and Executive Director

Hong Kong, China, December 9, 2022

As at the date of this announcement, the Board comprises Dr. De-Chao Michael Yu as Chairman and Executive Director and Mr. Ronald Hao Xi Ede as Executive Director, and Dr. Charles Leland Cooney, Ms. Joyce I-Yin Hsu, Dr. Kaixian Chen and Mr. Gary Zieziula as Independent Non-executive Directors.